Halozyme Therapeutics Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: halozyme.com
Recent Analyst Ratings for Halozyme Therapeutics Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/7/2024 | $58.00 → $62.00 | Overweight → Equal Weight | Wells Fargo |
9/19/2024 | $52.00 → $57.00 | Overweight → Neutral | JP Morgan |
6/7/2024 | $48.00 → $51.00 | Overweight → Neutral | Piper Sandler |
2/29/2024 | $54.00 | Outperform | TD Cowen |
7/24/2023 | $61.00 | Buy | H.C. Wainwright |
7/24/2023 | $43.00 → $45.00 | Buy → Neutral | Goldman |
5/10/2023 | $46.00 | Neutral → Overweight | Piper Sandler |
3/27/2023 | $58.00 | Buy | Berenberg |
3/16/2023 | $42.00 | Outperform → Market Perform | SVB Securities |
12/21/2022 | $53.00 → $65.00 | Overweight | Morgan Stanley |
Halozyme Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance Reiterating 2025 Finan
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813760. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharm
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I871904593. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available follow
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID). HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of I
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. "We are pleased that VYVDURA, with our innovative ENHANZE drug
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE® drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo® indications as monotherapy, monotherapy maintenance following completi
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follows: Event: Piper Sandler 36th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial Officer Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, December 4, 2024 Presentation Time: 10:30am PT / 1:30pm ET Location: New York, NY Event: 7th Annual Evercore ISI HealthCONx Conference Presenter: Helen Torley, President and Chief Executive Officer Format: Fireside Chat and 1x1 M
Halozyme Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Halozyme Therapeutics downgraded by Wells Fargo with a new price target
Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously
Halozyme Therapeutics downgraded by JP Morgan with a new price target
JP Morgan downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $57.00 from $52.00 previously
Halozyme Therapeutics downgraded by Piper Sandler with a new price target
Piper Sandler downgraded Halozyme Therapeutics from Overweight to Neutral and set a new price target of $51.00 from $48.00 previously
TD Cowen initiated coverage on Halozyme Therapeutics with a new price target
TD Cowen initiated coverage of Halozyme Therapeutics with a rating of Outperform and set a new price target of $54.00
H.C. Wainwright initiated coverage on Halozyme Therapeutics with a new price target
H.C. Wainwright initiated coverage of Halozyme Therapeutics with a rating of Buy and set a new price target of $61.00
Halozyme Therapeutics downgraded by Goldman with a new price target
Goldman downgraded Halozyme Therapeutics from Buy to Neutral and set a new price target of $45.00 from $43.00 previously
Halozyme Therapeutics upgraded by Piper Sandler with a new price target
Piper Sandler upgraded Halozyme Therapeutics from Neutral to Overweight and set a new price target of $46.00
Berenberg resumed coverage on Halozyme Therapeutics with a new price target
Berenberg resumed coverage of Halozyme Therapeutics with a rating of Buy and set a new price target of $58.00
Halozyme Therapeutics downgraded by SVB Securities with a new price target
SVB Securities downgraded Halozyme Therapeutics from Outperform to Market Perform and set a new price target of $42.00
Morgan Stanley resumed coverage on Halozyme Therapeutics with a new price target
Morgan Stanley resumed coverage of Halozyme Therapeutics with a rating of Overweight and set a new price target of $65.00 from $53.00 previously
Halozyme Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. sold $1,260,681 worth of shares (21,697 units at $58.10), decreasing direct ownership by 11% to 173,756 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. converted options into 4,747 shares and covered exercise/tax liability with 2,410 shares, increasing direct ownership by 1% to 195,453 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 7,012 shares and covered exercise/tax liability with 3,775 shares, increasing direct ownership by 13% to 28,489 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole converted options into 6,688 shares and covered exercise/tax liability with 3,601 shares, increasing direct ownership by 11% to 31,900 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
PRESIDENT AND CEO Torley Helen converted options into 22,436 shares and covered exercise/tax liability with 12,081 shares, increasing direct ownership by 1% to 733,719 units (SEC Form 4)
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SEC Form 4 filed by SVP, CHIEF TECHNICAL OFFICER Labarre Michael J.
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SEC Form 4 filed by SVP, CHIEF LEGAL OFFICER Snyder Mark Howard
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
SEC Form 4 filed by PRESIDENT AND CEO Torley Helen
4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
Halozyme Therapeutics Inc. SEC Filings
Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SEC Form DEFA14A filed by Halozyme Therapeutics Inc.
DEFA14A - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SEC Form DEF 14A filed by Halozyme Therapeutics Inc.
DEF 14A - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SEC Form 10-K filed by Halozyme Therapeutics Inc.
10-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SEC Form 10-Q filed by Halozyme Therapeutics Inc.
10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
SEC Form 144 filed by Halozyme Therapeutics Inc.
144 - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
Halozyme Therapeutics Inc. Leadership Updates
Live Leadership Updates
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.
Halozyme Appoints Barbara Duncan to its Board of Directors
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance experience to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Barbara's business leadership, financial expertise and board experience will add important insights and contributions to the continuing success and growth of the company." Ms. Duncan
Halozyme Appoints Moni Miyashita to Board of Directors
SAN DIEGO, March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished executive with over 25 years of global strategic, mergers & acquisitions and business transformation expertise. "We are delighted to welcome an executive with Moni's broad experience and strategic vision to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "Moni's deep experience in corporate strategy, mergers & acquisitions and risk management across multiple industries strongly complements our board's expertise as we focus on expanding and extending the growth oppor
Halozyme Appoints New Chief Financial Officer
SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity. Ms. LaBrosse brings over 18 years of public accounting and corporate finance experience to Halozyme. Ms. LaBrosse joined Halozyme in 2015 and has since held roles of growing responsibility within the Company. Most recently, Ms. LaBrosse served as Halozyme's vice president, finance and accounting since 2020. Previously, Ms. LaBrosse held the role of executive director, controll
HALOZYME APPOINTS NEW GENERAL COUNSEL
SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue another opportunity. Mr. Snyder brings almost thirty years of legal and business experience to Halozyme. Over his career he has led and played key roles in a broad range of intellectual property, licensing, regulatory, anti-trust and litigation matters. Most recently Mr. Snyder served as senior vice president, deputy general counsel, litigation for Qualcomm Incorporated,
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2021 financial guidance and commented on its outlook for the year. "2020 was a year of tremendous accomplishment at Halozyme highlighted by our successful transition to revenue growth and profitability, 2 U.S. FDA approvals and 2 European Commission approvals for ENHANZE® partner products, and successful completion of $150 million in share repurchases in 2020," said Dr. Helen Torley, president and chief executive officer. "We are delighted with the strong first six months post launch market adoption of DARZALEX FASPRO® in the US, which drove a return to royalty revenue growth in 2020. In
Halozyme Therapeutics Inc. Financials
Live finance-specific insights
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance Reiterating 2025 Finan
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813760. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharm
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I871904593. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available follow
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its fina
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845). "We remain confident in our strong royalty revenue projections with 8 approved partne
Halozyme to Report Third Quarter 2024 Financial and Operating Results
SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical comp
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.911 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22%, Adjusted EBITDA of $555 - $615 million, Representing YOY Growth of 30% - 44% and Non-GAAP Diluted EPS of $3.65 - $4.05, Representing YOY Growth of 32% - 46% SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") t
Halozyme to Report Second Quarter 2024 Financial and Operating Results
SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "We are pleased to be able to raise our full year 2024
Halozyme Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G filed by Halozyme Therapeutics Inc.
SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)
SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)